Adamis’shares nosedive as sole clinical-stage asset flunks COVID-19 trial Bay state biotechs Sesen and Carismablend together in bid to transform cancer treatment Cash-depleted Acerusundergoes strategic review to stay afloat Puma pounces onfailed Takeda drug, snapping up cancer prospect for knockdown price Rise of the machines: Novo Nordiskpledges $200M to create first quantum computer for life sciences AbCellera doubles down on Vancouver, kicking off 2nd expansion phase to build integrated antibody R&D shop |